No Detail Found!

ß-Thalassemia major: Bone Marrow versus peripheral Blood Stem Cell Transplantation.

Author(s)
Muhammad Irfan Section of Pulmonary Medicine, The Aga Khan University Hospital, Karachi, Pakistan
Khalil Hashmi Armed Forces Institute of Bone Marrow Transplantation, Rawalpindi, Pakistan
Salman Adil Department of Pathology and Microbiology, Aga Khan University Hospital, Karachi, Pakistan
Tahir Shamsi Dr. Ziauddin Hospital, Karachi, Pakistan
Tasneem Farzana Bismillah Taqee Institute of Health Sciences and Blood Diseases Centre, Karachi, Pakistan
Saquib Ansari Bismillah Taqee Institute of Health Sciences and Blood Diseases Centre, Karachi, Pakistan
Vinodh Panjwani Bismillah Taqee Institute of Health Sciences and Blood Diseases Centre, Karachi, Pakistan
Pervaiz Ahmed Department of Pathology, Combined Military Hospital, Lahore, Pakistan
Badshah Khan Department of Pathology, Combined Military Hospital, Lahore, Pakistan
Abstract
Objective: To compare PBSCT with BMT in Thalassaemia patients in terms of rejection, non-rejection mortality, disease free survival and overall survival. Methods: Fifty six patients were transplanted from September 2000 - July 2005. Twenty nine underwent BMT and 27 received PBSCT. Most patients were intensely transfused to keep minimum haemoglobin of 12 gm/dl and received desferioxamine, 24 hours infusion, before transplantation. Pesaro class I (n-20) and class II (n-20) received conditioning with standard Bu/Cy. Of class III (n-16), ALG was added to standard Bu/Cy in 9 who received PBSCT and 7, who received BM, were conditioned with Hydrea 20-30 mg / kg (day - 45 to -11), Azathioprin 2-3 mg / kg (day - 45 to day -11), Fludarabine 25 mg / kg (day -17 to -13) followed by Bu14 / Cy 200 started on day - 10. Triple immunosuppression was used for whole PBSC group and class III-BM group. For others, a GvHD prophylaxis comprised of MTX and cyclosporine only. MNC dose infused was > 4 x 108/kg (range 4.8-8.2) recipient weight in PBSC patients and for BM its range was 1.6 - 5.2 MNC / kg . All patients received GCSF 5mg / kg / day, from day + 5, till ANC > 0.5x109 / l. Median age of the donor was 8.6 years. All recipients and donors were genotypically HLA matched except in one. PBSC were harvested on day 5 of G-CSF administration. Follow up ranged from 273 - 2088 days. Results: Median age for BM and PBSC group was 5.2 and 6.9 years. Engraftment was achieved in all cases. Median time to ANC of 0.5 x 109/ l in BMT / PBSCT patients was 13 / 10 days (range 11-19 / 9 - 15) and for platelets of 20 x 109 / l it was 17 / 14 days (range 14 - 28 / 12 - 19). aGvHD (grade II - IV) was seen in 30% / 26% cases in BMT / PBSCT group. Incidence and severity of chronic GvHD was not statistically different in two groups (BM-24% & PBSC -30%). Six patients rejected the graft. Of the four who rejected the graft from class III, 3 were from PBSC group. DFS in risk classes of the two groups was not significant. Overall survival / disease free survival for the BM and PBSC group as on December 2005 was 73% / 65% and 67% / 55%. Conclusion: This study shows that major outcomes with PBSCT are not statistically different from BMT. Rejection and disease free survival in class 3 patients who received intensified immuno-suppression and large doses of PBSC is comparable to BM group who were conditioned according to newer Lucrali protocol
Publication Details
Page(s) 107-110
DOI DOI not available
Published Journal: Journal of Pakistan Medical Association, Volume: 58, Issue: 3, Year: 2008

Request the full text from PASTIC

0

Citations

0

Downloads

55

Views